The final quarter of 2019 proved to be a lucrative one for biopharma companies, which pulled in $15.8bn in financing, a 19% increase over Q3’s $13.3bn total. (See Exhibit 1.) Q4 also turned out to be the second-strongest quarter of the year for fundraising.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?